Long Acting Platform Camurus' FluidCrystal technology enables best-in-class potential for long-acting medicines, creating licensing or co-development opportunities for partners seeking differentiated delivery in opioid dependence, cancer, and endocrine disorders. The pipeline combines in-house development with external collaborations, offering multiple entry points for business development and manufacturing partnerships.

Targeted Therapeutic Focus The current pipeline areas of opioid dependence, cancer, and endocrine disorders align with high-need markets and payer interest in extending drug durability and adherence, presenting viable opportunities for strategic alliances, co-development, and licensing of long-acting formulations.

Regulatory Readiness ISO 13485 and established quality systems signal strong regulatory and manufacturing readiness, enabling Camurus to pursue contract development, manufacturing, and global distribution partnerships with reduced regulatory friction.

Investor Partnerships With revenue in the hundreds of millions and external funding, Camurus demonstrates financial momentum and appetite for strategic deals, including licensing, co-development, or milestone-based collaborations to accelerate pipeline progression.

European Footprint Based in Lund, Sweden and listed on Nasdaq Stockholm, Camurus offers a European-market access advantage, potential for cross-border collaboration with European pharma and healthcare stakeholders, and alignment with sustainability and patient-centric care themes.